Mechanistic Aspects and Novel Biomarkers of Responder and Non-Responder Phenotypes in Galactosamine-Induced Hepatitis
Open Access
- 12 October 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 8 (11) , 5175-5187
Abstract
The amino sugar galactosamine (galN) induces alterations in the hepatic uridine nucleotide pool and has been widely used as a model of human viral hepatitis. Histopathological and clinical chemistry analyses of a cohort of rats following administration of galN revealed extreme interindividual variability in the extent of the toxic response which enabled classification of ‘responder’ and ‘non-responder’ phenotypes. An integrative metabolic profiling approach was applied to characterize biomarkers of exposure to galN in urine, serum, feces and liver from responders and non-responders. The presence of N-acetylglucosamine and galN in the urine correlated with the occurrence and extent of toxic response. Conversely, the novel identification of galN-pyrazines in the feces of non-responders and their virtual absence in the feces of responders suggests an alternative means of distribution and metabolism of galN in non-responders. The absence of the UDP-hexosamines in the liver of non-responders further supports differential metabolism of galN and suggests an ability of non-responders to avoid UDP-glucose depletion. An observed disturbance of gut microbial derived metabolites in the urine and feces of non-responders may suggest a role of the microflora in reducing the effective dose of galN. This systems level metabonomic approach has provided new mechanistic insights into differential response to galN and is widely applicable to the study of interindividual variation in metabolism for any xenobiotic intervention.Keywords
This publication has 71 references indexed in Scilit:
- The Consortium for Metabonomic Toxicology (COMET): Aims, Activities and AchievementsPharmacogenomics, 2005
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET projectToxicology and Applied Pharmacology, 2003
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Nuclear Magnetic Resonance Spectroscopic and Principal Components Analysis Investigations into Biochemical Effects of Three Model HepatotoxinsChemical Research in Toxicology, 1998
- Dual Role of Hexose-1-phosphate Uridylyltransferase in Galactosamine MetabolismEuropean Journal of Biochemistry, 1982
- Galactosamine hepatitis: Key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death1974
- Selective Uridine Triphosphate Deficiency Induced by d-Galactosamine in Liver and Reversed by Pyrimidine Nucleotide PrecursorsJournal of Biological Chemistry, 1974
- The Trapping of Uridine Phosphates byd‐Galactosamine,d‐Glucosamine, and 2‐Deoxy‐d‐galactoseEuropean Journal of Biochemistry, 1970
- The metabolism of d-galactosamine and N-acetyl-d-galactosamine in rat liverBiochemical Journal, 1968